Hikma Pharmaceuticals Plc Total Voting Rights (9826A)
04 January 2018 - 10:19PM
UK Regulatory
TIDMHIK
RNS Number : 9826A
Hikma Pharmaceuticals Plc
04 January 2018
Hikma Pharmaceuticals PLC
Total Voting Rights and Capital
LONDON, 4 January 2018 - In accordance with the UK Financial
Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals
PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)
notifies the market that as at 31 December 2017, its share capital
consists of 240,678,894 ordinary shares with voting rights. There
are nil shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FCA's DTR's.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2016, Hikma achieved
revenues of $1,950 million and profit attributable to shareholders
of $155 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAFFLEFNPEFF
(END) Dow Jones Newswires
January 04, 2018 06:19 ET (11:19 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024